| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6099857 | Journal of Crohn's and Colitis | 2013 | 10 Pages |
Abstract
Oral treatment with the selective small molecule α4 integrin antagonist (AJM300) prevented the development of colitis and its efficacy was comparable to that of the anti-α4 integrin antibody.
Keywords
PBSMAdCAM-1VCAM-1CTRLHEKSCIDICAM-1IBDDAPIIL-104′,6-diamidino-2-phenylindoleInterleukin-10Inflammatory bowel diseaseOral drugPharmacodynamicsPharmacokineticsLymphocyte homingPhosphate-buffered salineintercellular adhesion molecule-1mucosal addressin cell adhesion molecule-1vascular cell adhesion molecule-1human embryonic kidneyControl
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Toshihiko Sugiura, Shunsuke Kageyama, Ayatoshi Andou, Tomoko Miyazawa, Chieko Ejima, Akira Nakayama, Taeko Dohi, Hiroyuki Eda,